Gadobenate Dimeglumine
Mechanism :
Gadobenate dimeglumine is a gadolinium-based contrast agent. After intravenous administration, the meglumine salt dissociates and the gadobenate ion conforms into a 2-compartment pharmacokinetic model.
It distributes in the extracellular body water.
Indication :
- For contrast enhancement in MRI during CNS imaging: to visualise lesions with an atypical blood-brain barrier or atypical vascularity.
Contraindications :
• Contrast hypersensitivity
• Use cautiously in renal impairment
• Use cautiously in sickle cell disease
• Use cautiously in arrythmias and QT prolongation
• Use cautiously in pediatric population
• Ensure there is no extravasation while administration of contrast
Dosing :
Available as a solution: 529 mg/mL.
Adolescents and infants: 0.2 mL/kg or 0.1 mmol/kg IV single dose.
Term neonates: 0.2 mL/kg or 0.1 mmol/kg IV single dose.
Preterm neonates: Safety and efficacy unknown.
Adverse Effect :
Nausea, headache, paresthesias, dizziness, hyperhidrosis, fever, dysgeusia, injection site reactions.
Interaction :
• Anthracyclines
• Cisplatin
• Daunorubicin
• Doxorubicin
• Epirubicin
• Etoposide
• Idarubicin
• Methotrexate
• Paclitaxel
• Vinca alkaloids
Lactation :
Effect on infant unknown due to limited data availability
Hepatic Dose :
Dosage adjustments are not recommended.
Pregnanacy :
Effect on fetus unknown due to limited data availability